Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > If ATE

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Mar 01, 2024 9:35pm

225 Views

Post# 35910723

RE:RE:RE:RE:If ATE

From a shareholder with warrants perspective - If you truly want shares, you bought at 50 cents or you buy now - below a dollar.
you already have shares and the warrants are your bonus ... if bonus can be paid.

From ATE's perspective - this is easy money in the bank if you can convert the share price to over $2 by March 29th. If you can't, you still have one more chance to convert to $3 by July 29th.

That's how I see it.

Have shares and want shares ? Then buy when below a dollar.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec